In November 2020, the FDA approved the first intratumoral [intra-TU-moral] drug to treat local canine mast cell tumors that haven’t spread. These tumors are the most common skin malignancies in...
In November 2020, the FDA approved the first intratumoral [intra-TU-moral] drug to treat local canine mast cell tumors that haven’t spread. These tumors are the most common skin malignancies in...